183.65 USD
+9.12 (+5.23%)
183.65 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to ICLR. ICLR was compared to 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. ICLR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ICLR had positive earnings in the past year.
ICLR had a positive operating cash flow in the past year.
In the past 5 years ICLR has always been profitable.
Each year in the past 5 years ICLR had a positive operating cash flow.
1.2 Ratios
ICLR has a better Return On Assets (3.63%) than 75.86% of its industry peers.
ICLR has a Return On Equity of 6.42%. This is in the better half of the industry: ICLR outperforms 75.86% of its industry peers.
The Return On Invested Capital of ICLR (6.74%) is better than 75.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 13.53%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.74%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROIC | 6.74% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
The Profit Margin of ICLR (7.40%) is better than 75.86% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 13.99%, ICLR is in the better half of the industry, outperforming 75.86% of the companies in the same industry.
In the last couple of years the Operating Margin of ICLR has remained more or less at the same level.
ICLR has a worse Gross Margin (28.15%) than 74.14% of its industry peers.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
The debt/assets ratio for ICLR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.12 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score of 2.12. This is comparable to the rest of the industry: ICLR outperforms 48.28% of its industry peers.
ICLR has a debt to FCF ratio of 3.53. This is a good value and a sign of high solvency as ICLR would need 3.53 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.53, ICLR is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
A Debt/Equity ratio of 0.31 indicates that ICLR is not too dependend on debt financing.
ICLR's Debt to Equity ratio of 0.31 is in line compared to the rest of the industry. ICLR outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Altman-Z | 2.12 |
ROIC/WACC0.81
WACC8.34%
2.3 Liquidity
A Current Ratio of 1.06 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR's Current ratio of 1.06 is on the low side compared to the rest of the industry. ICLR is outperformed by 87.93% of its industry peers.
ICLR has a Quick Ratio of 1.06. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ICLR (1.06) is worse than 79.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
The earnings per share for ICLR have decreased by -5.99% in the last year.
Measured over the past years, ICLR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.23% on average per year.
The Revenue has decreased by -2.46% in the past year.
ICLR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.17% yearly.
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
3.2 Future
Based on estimates for the next years, ICLR will show a small growth in Earnings Per Share. The EPS will grow by 5.61% on average per year.
ICLR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.38% yearly.
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.92, the valuation of ICLR can be described as correct.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 96.55% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.15.
The Price/Forward Earnings ratio is 13.30, which indicates a correct valuation of ICLR.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 96.55% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ICLR to the average of the S&P500 Index (36.12), we can say ICLR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.92 | ||
| Fwd PE | 13.3 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 100.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 94.83% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.81 | ||
| EV/EBITDA | 11.31 |
4.3 Compensation for Growth
ICLR has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.91
EPS Next 2Y-0.67%
EPS Next 3Y3%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
183.65
+9.12 (+5.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.62%
Inst Owner Change-0.43%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap14.28B
Revenue(TTM)8.10B
Net Income(TTM)599.48M
Analysts76.67
Price Target209.8 (14.24%)
Short Float %2.44%
Short Ratio1.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.77%
Min EPS beat(2)-1.21%
Max EPS beat(2)-0.34%
EPS beat(4)1
Avg EPS beat(4)-0.63%
Min EPS beat(4)-1.21%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.34%
EPS beat(12)2
Avg EPS beat(12)-1.79%
EPS beat(16)5
Avg EPS beat(16)-1.4%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.23%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-2.61%
Max Revenue beat(4)1.03%
Revenue beat(8)1
Avg Revenue beat(8)-2.24%
Revenue beat(12)1
Avg Revenue beat(12)-2.14%
Revenue beat(16)1
Avg Revenue beat(16)-2.06%
PT rev (1m)-4.69%
PT rev (3m)-5.91%
EPS NQ rev (1m)-3.7%
EPS NQ rev (3m)-5.84%
EPS NY rev (1m)-1.01%
EPS NY rev (3m)-1.62%
Revenue NQ rev (1m)1.53%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)0.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.92 | ||
| Fwd PE | 13.3 | ||
| P/S | 1.76 | ||
| P/FCF | 14.81 | ||
| P/OCF | 12.52 | ||
| P/B | 1.53 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.31 |
EPS(TTM)13.19
EY7.18%
EPS(NY)13.81
Fwd EY7.52%
FCF(TTM)12.4
FCFY6.75%
OCF(TTM)14.66
OCFY7.98%
SpS104.19
BVpS120.03
TBVpS-38.28
PEG (NY)N/A
PEG (5Y)0.91
Graham Number188.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.63% | ||
| ROE | 6.42% | ||
| ROCE | 8.53% | ||
| ROIC | 6.74% | ||
| ROICexc | 6.98% | ||
| ROICexgc | 176.34% | ||
| OM | 13.99% | ||
| PM (TTM) | 7.4% | ||
| GM | 28.15% | ||
| FCFM | 11.9% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexgc growth 3Y-4.45%
ROICexgc growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score6
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.31 | ||
| Debt/FCF | 3.53 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 45.31% | ||
| Cap/Sales | 2.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.92% | ||
| Profit Quality | 160.84% | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 2.12 |
F-Score6
WACC8.34%
ROIC/WACC0.81
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.99%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-1.19%
EPS Next Y-4.67%
EPS Next 2Y-0.67%
EPS Next 3Y3%
EPS Next 5Y5.61%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%0.63%
Revenue Next Year-2.45%
Revenue Next 2Y-0.8%
Revenue Next 3Y0.9%
Revenue Next 5Y2.38%
EBIT growth 1Y-0.88%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year0.82%
EBIT Next 3Y3.29%
EBIT Next 5Y4.34%
FCF growth 1Y86.71%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y72.39%
OCF growth 3Y15.78%
OCF growth 5Y25.55%
ICON PLC / ICLR FAQ
Can you provide the ChartMill fundamental rating for ICON PLC?
ChartMill assigns a fundamental rating of 5 / 10 to ICLR.
What is the valuation status of ICON PLC (ICLR) stock?
ChartMill assigns a valuation rating of 6 / 10 to ICON PLC (ICLR). This can be considered as Fairly Valued.
Can you provide the profitability details for ICON PLC?
ICON PLC (ICLR) has a profitability rating of 6 / 10.
How financially healthy is ICON PLC?
The financial health rating of ICON PLC (ICLR) is 5 / 10.
What is the earnings growth outlook for ICON PLC?
The Earnings per Share (EPS) of ICON PLC (ICLR) is expected to decline by -4.67% in the next year.